ÊÀ½çÐÂÒ©¸ÅÀÀ-2014Äê¾í

Executive SummaryCHAPTER1£®Alectinib HydrochlorideCHAPTER2£®Apatinib MesylateCHAPTER3£®ApremilastCHAPTER4.AsunaprevirCHAPTER5£®AtalurenCHAPTER6£®BelinostatCHAPTER7£®CeritinibCHAPTER8£®ChidamideCHAPTER9£®Daclatasvir DihydrochlorideCHAPTER10£®DelamanidCHAPTER11£®EliglustatTartrateCHAPTER12£®EmpagliflozinCHAPTER13£®FinafloxacinCHAPTER14£®IdelalisibCHAPTER15£®IpragliflozinL£®ProlineCHAPTER16£®Luseogliflozin HydrateCHAPTER17£®Naloxegol OxalateCHAPTER18£®Nintedanib EsylateCHAPTER19£®OlaparibCHAPTER20£®Oritavancin DiphosphateCHAPTER21£®PhenothrinCHAPTER22£®Ripasudil Hydrochloride HyrdrateCHAPTER23£®SuvorexantCHAPTER24£®TasimelteonCHAPTER25£®TavaboroleCHAPTER26£®Tedizolid PhosphateCHAPTER27£®Tofogliflozin HydrateCHAPTER28£®Umeclidinium BromideCHAPTER29£®VaniprevirCHAPTER30£®VonoprazanFumarateCHAPTER31£®VorapaxarSulfateAppendix.AbbreviationAppendixII.SalesWorldwider2014¡ª2015)AppendixIII.WorldwideApproved NCEs(2001¡ª2015)Append&IV.WorldwideApproved NCEs(SortedbyIndication2001¡ª2015)